|
|
||||||||
Receptor 2 with Dominant Negative Activity: Biological Consequences of Homozygous and Heterozygous States1





* Laboratory of Host Defenses, and
Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, and
Clinical Immunology Laboratory, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892; and
Departments of Pediatrics and Immunology, Duke University Medical Center, Durham, NC 27710
We identified two siblings homozygous for a single base pair deletion in the IFN-
R2 transmembrane domain (791delG) who presented with multifocal Mycobacterium abscessus osteomyelitis (patient 1) and disseminated CMV and Mycobacterium avium complex infection (patient 2), respectively. Although the patients showed no IFN-
R activity, their healthy heterozygous parents showed only partial IFN-
R activity. An HLA-identical bone marrow transplant from the mother led patient 1 to complete hemopoietic reconstitution, but only partial IFN-
R function. We cloned and expressed fluorescent fusion proteins of the wild-type IFN-
R2, an IFN-
R2 mutant previously described to produce a complete autosomal recessive deficiency (278del2), and of 791delG to determine whether the intermediate phenotype in the 791delG heterozygous state was caused by haploinsufficiency or a dominant negative effect. When cotransfected together with the wild-type vector into IFN-
R2-deficient fibroblasts, the fusion protein with 791delG inhibited IFN-
R function by 48.7 ± 5%, whereas fusion proteins with 278del2 had no inhibitory effect. Confocal microscopy of 791delG fusion proteins showed aberrant diffuse intracellular accumulation without plasma membrane localization. The fusion protein created by 791delG did not complete Golgi processing, and was neither expressed on the plasma membrane, nor shed extracellularly. The mutant construct 791delG exerts dominant negative effects on IFN-
signaling without cell surface display, suggesting that it is acting on pathways other than those involved in cell surface recognition of ligand.
This article has been cited by other articles:
![]() |
S Y Patel, R Doffinger, G Barcenas-Morales, and D S Kumararatne Genetically determined susceptibility to mycobacterial infection J. Clin. Pathol., September 1, 2008; 61(9): 1006 - 1012. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Vogt, J. Bustamante, A. Chapgier, J. Feinberg, S. Boisson Dupuis, C. Picard, N. Mahlaoui, L. Gineau, A. Alcais, C. Lamaze, et al. Complementation of a pathogenic IFNGR2 misfolding mutation with modifiers of N-glycosylation J. Exp. Med., August 4, 2008; 205(8): 1729 - 1737. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Sexton and A. C. Harrison Susceptibility to nontuberculous mycobacterial lung disease Eur. Respir. J., June 1, 2008; 31(6): 1322 - 1333. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Greendyke and T. F. Byrd Differential Antibiotic Susceptibility of Mycobacterium abscessus Variants in Biofilms and Macrophages Compared to That of Planktonic Bacteria Antimicrob. Agents Chemother., June 1, 2008; 52(6): 2019 - 2026. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Bustamante, C. Picard, C. Fieschi, O. Filipe-Santos, J. Feinberg, C. Perronne, A. Chapgier, L. de Beaucoudrey, G. Vogt, D. Sanlaville, et al. A novel X-linked recessive form of Mendelian susceptibility to mycobaterial disease J. Med. Genet., February 1, 2007; 44(2): e65 - e65. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Filipe-Santos, J. Bustamante, M. H. Haverkamp, E. Vinolo, C.-L. Ku, A. Puel, D. M. Frucht, K. Christel, H. von Bernuth, E. Jouanguy, et al. X-linked susceptibility to mycobacteria is caused by mutations in NEMO impairing CD40-dependent IL-12 production J. Exp. Med., July 10, 2006; 203(7): 1745 - 1759. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Rosenzweig, O. M. Schwartz, M. R. Brown, T. L. Leto, and S. M. Holland Characterization of a Dipeptide Motif Regulating IFN-{gamma} Receptor 2 Plasma Membrane Accumulation and IFN-{gamma} Responsiveness J. Immunol., September 15, 2004; 173(6): 3991 - 3999. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |